GE Healthcare Life Sciences is building a new manufacturing facility, in the new Signy Park, in Grens, Switzerland.
The main focus of the 7,360 square meter facility will be the manufacture of single-use kits for the Sepax and Sefia cell processing systems.
The Sepax and Sefia cell processing systems are intended to automate processing steps during cell and gene therapy development.
Through the use of a separation chamber manifolded to cell bags, these kits enable a variety of protocols including Cellwash, Culture Wash, Adipose protocols, Dilution, Cell Harvesting, and Expansion.
However, it will also house a Center of Excellence that will include advanced cell and gene therapy manufacturing facilities, as well as an R&D team.
The facility will also serve as a base for European customer training and educational initiatives.
The site is expected to be fully operational in 2022 and will be able to house up to 200 employees.
|GE Healthcare Life Sciences